New England drug developers made headlines this week with funding news.
—My San Diego colleague Bruce took a look at Applied Proteomics, the five-year-old biotech startup co-founded by MIT-trained computer scientist Danny Hillis. The startup, which raised $22.5 million in funding in... Read more »
—It wasn’t exactly news when the board at San Diego-based Illumina (NASDAQ: ILMN) said it had rejected the $5.7 billion hostile takeover offer from Swiss drug maker Roche. Now Wall Street’s arbitragers are placing their bets on whether Roche can... Read more »
When Barry Fogel first started developing a new treatment 15 years ago, his main goal was to help his own patients. Fogel, a physician trained in both psychiatry and neurology, saw many patients with a movement disorder called tardive dyskinesia (TD). The condition—which can be... Read more »
New England Patriots owner Robert Kraft may still be smarting from his team’s loss to the New York Giants in the Super Bowl, but at least one of Kraft’s other organizations has some good news to cushion the blow: Boston-based Acetylon... Read more »
New York is home to several organizations that are uniting the city’s disparate academic institutions in pursuit of common goals. This month will mark the opening of the New York Genome Center, an effort among 11 colleges to collaborate on genomics... Read more »
OncoSec Medical CEO Punit Dhillon tells me the startup he helped establish in San Diego last March is beginning mid-stage safety and efficacy trials of its proprietary technology for enhancing drug delivery in treatments of several types of skin cancer.
The technology,... Read more »
Plans for IPOs and venture funding dominated the New England deals news this week.
—A new seed fund, backed by venture firm New Enterprise Associates and hosted by Harvard, came out of the woodwork last week. The Experiment Fund will invest up... Read more »